Bone News and Research

RSS

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009

Stem cells - the answer to autoimmune diseases and cancer in the future

Stem cells are multipotent cells of the immune system. Scientists hope to use them for curing autoimmune diseases, cancer and innate genetic defects in the future.

16 Sep 2009

Research study conducted to understand radiation-induced bone loss

A research project looking for ways to reduce bone loss in astronauts may yield methods of improving the bone health of cancer patients undergoing radiation treatment.

16 Sep 2009

HemoRANK-TKI in vitro assay service package from ReachBio

ReachBio LLC announced today the launch of HemoRANK(TM)-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia).

16 Sep 2009

Laser technology lowers manufacturing cost of artificial joints and arterial stents

Researchers are developing technologies that use lasers to create arterial stents and longer-lasting medical implants that could be manufactured 10 times faster and also less expensively than is now possible.

16 Sep 2009

Governor’s Business Expansion Award for RTI Biologics

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, was awarded the 2009 Governor’s Business Expansion Award from Florida Governor Charlie Crist today.

16 Sep 2009

FDA clears Olerup SSP’s Taq-polymerase-free HLA typing kit for sale in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed (STO:LMED), has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America.

15 Sep 2009

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

New hydrogel mats extends anti-infection protection

Treatment of hospital-related infections in the U.S. costs up to $11 billion a year and about half of those infections are related to medical devices implanted in patients. Until now, efforts to control drug-resistant biofilms on such devices have been largely unsuccessful.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.

15 Sep 2009

Studies to focus on treatments for traumatic battlefield injuries

The University of Maryland R Adams Cowley Shock Trauma Center in Baltimore, Md., will serve as one of 12 core clinical centers in a newly established Extremity Trauma Clinical Research Consortium funded by the U.S. Department of Defense.

15 Sep 2009

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University Medical Center has received a $2 million matching grant from The Coleman Foundation to renovate the hospital's nationally known bone marrow transplant unit. Intended to encourage private donations for the project, the grant will match gifts up to $2 million on a dollar for dollar basis, through August 2010.

15 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

FDA clearance for PRO-STIM bone graft substitute

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the 510K clearance of PRO-STIM™ Injectable Osteoinductive Bone Graft Substitute. PRO-STIM™ graft is a composite grafting material that is injected through a small needle, hardens, and is replaced by the patient’s new bone over time.

14 Sep 2009

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor development.

14 Sep 2009

IVIS Lumina XR in vivo imaging system from Caliper Life Sciences

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family.

14 Sep 2009